Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Tavi Procedure

Research Leaders

6 sponsors active, led by AstraZeneca

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 4 (1)

Trial Status

Completed1
Recruiting1
Terminated1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05152888Phase 4RecruitingPrimary

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

NCT02797158Not ApplicableCompleted

Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study

NCT01122719Not ApplicableTerminatedPrimary

Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen

NCT02214654Unknown

A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage

Showing all 4 trials

Research Network

Common Treatments

  • Tavi Procedure1
  • Drug Eluting Stent1
  • Evolocumab1

Active Sponsors

  • AstraZeneca1
  • Contract research Organization: Cardiovascular Research Center - Sao Paulo, Brazil1
  • Brigham and Women's Hospital1
  • Tianjin Medical University1
  • CID - Carbostent & Implantable Devices1

Top Investigators

Related Conditions

  • Severe And Symptomatic Aortic Stenosis1
  • Documented Silent Ischemia1
  • Type 2 Diabetes Mellitus1
  • Unstable Coronary Disease1

Activity Timeline